Skip to main content

Table 5 Time to symptom clearance for individual symptoms by day 10

From: Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial

 

Arm 1:

HCQ + SOC

Arm 2:

SOC

 

No. patients

Median (IQR) days

No. patients

Median (IQR) days

Overall

36

3 (2–5)

29

3 (2–4)

General symptoms

    

 Fever

5

1 (1–2)

4

1 (1–3)

 Tiredness

5

1 (1–1)

3

1 (1–2)

 Muscle aches

4

2 (1–3)

5

1 (1–1)

Cardio-respiratory symptoms

 Cough

20

3 (2–4)

14

4 (2–5)

 Running nose

11

1 (1–3)

4

2 (1–3)

 Nasal congestion

4

4 (3–5)

3

2 (1–5)

 Sore throat

3

1 (1–3)

2

1 (1–1)

 Difficulty in breathing

1

1 (1–1)

0

0

 Chest pain

7

1 (1–4)

5

2 (1–3)

Neurological symptoms

    

 Headache

14

2 (1–3)

11

2 (1–5)

 Dizziness

1

1 (1–1)

3

2 (1–4)

 Loss of smell

6

2 (1–3)

4

1 (1–3)

 Loss of taste

4

1 (1–2)

4

1 (1–1)

Gastrointestinal

    

 Poor appetite

5

3 (1–5)

4

1 (1–2)

 Nausea

1

1 (1–1)

0

N/A

 Vomiting

1

1 (1–1)

0

N/A

 Abdominal pain

4

1 (1–3)

2

2 (1–3)

 Diarrhea

1

1 (1–1)

1

5 (5–5)